Bioverativ (NASDAQ:BIVV) will post its quarterly earnings results after the market closes on Tuesday, February 13th. Analysts expect Bioverativ to post earnings of $0.57 per share for the quarter.
Shares of Bioverativ (NASDAQ:BIVV) opened at $103.50 on Tuesday. Bioverativ has a 12 month low of $41.88 and a 12 month high of $104.30. The company has a market capitalization of $11,200.00 and a PE ratio of 25.31.
A number of research analysts have recently weighed in on the company. Credit Suisse Group reissued a “neutral” rating on shares of Bioverativ in a report on Wednesday, January 24th. Argus reissued a “hold” rating on shares of Bioverativ in a report on Wednesday, January 24th. Zacks Investment Research lowered Bioverativ from a “buy” rating to a “hold” rating in a report on Wednesday, January 3rd. Piper Jaffray Companies reissued an “overweight” rating and issued a $71.00 price objective on shares of Bioverativ in a report on Monday, October 23rd. Finally, Morgan Stanley raised Bioverativ from an “underweight” rating to an “equal weight” rating in a report on Tuesday, January 23rd. Thirteen research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Bioverativ presently has a consensus rating of “Hold” and a consensus price target of $62.86.
Bioverativ Company Profile
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.